1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

Global Blood therapeutics recently announced orphan drug designation for its leading product candidate GBT440 by European Commission for the treatment of Sickle cell disease (SCD), a severely distressing disease with limited treatment op...

Read More

---

FDA grants orphan drug designation to Viking Therapeutics’ VK0214 to treat X-ALD

Release Date: 04 January 2017

Viking Therapeutics (VXTX), a bio pharmaceutical company recently announced that its novel drug, VK 0214 has been granted orphan drug status by US Food and Drug Administration (FDA) for the treatment of X-linked adrenoleukodystrophy (X-A...

Read More

---

FDA declares BHV-0223 as orphan drug to treat ALS

Release Date: 03 January 2017

Biohaven declares that its leading treatment candidate, BHV-0223 received orphan drug designation from US Food and Drug Administration (FDA) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

 

Read More

---

Amryt receives orphan drug status for Episalvan

Release Date: 02 January 2017

Food and Drug administration (FDA) has declared orphan drug designation for Amryt Pharma’s leading treatment therapy Episalvan for the treatment of epidermolysis bullosa (EB). It is a rare and distressing genetic disorder affecting...

Read More

---

EU Union grants orphan drug designation to ARA 290

Release Date: 14 December 2016

Araim Pharmaceuticals, drug Development Company announced that its lead product, innate repair receptor activator ARA 290, has been designated as orphan drug by European Commission for the prevention of graft loss in pancreatic islet tra...

Read More

---

FDA grants orphan drug status to Keystone’s ceramides

Release Date: 14 December 2016

Keystone Nano has announced that its leading product, ceramides has received orphan drug status from U.S Food and Drug Administration (FDA) for the treatment of patients with liver cancer. Demonstration of ceramides have proved its effec...

Read More

---

Novel PAH treatment receives FDA orphan drug designation

Release Date: 13 December 2016

Reviva pharmaceuticals announced that U.S food and Drug designation has granted orphan drug designation to its leading drug candidate, RP5603 for the treatment of pulmonary arterial hypertension (PAH). RP5603 is a combination of chemical...

Read More

---

Omeros Corp. files for orphan drug status for OMS721 in Immunoglobin A Nephropathy

Release Date: 12 December 2016

Omeros Corp. has filed application for orphan drug designation to U.S Food and Drug Administration and European Commission for OMS721 in Immunoglobin A Nephropathy. The agency is planning to initiate OMS721 phase 3 programs in both IGA n...

Read More

---

Novel Hepatocellular Carcinoma Tx receives orphan drug status by FDA

Release Date: 11 December 2016

U.S Food and Drug Administration (FDA) have granted orphan drug designation to Yisheng Biopharma’s leading candidate, hepatocellular carcinoma treatment, YSON-001. The drug is complex in nature with multi-component structure of bro...

Read More

---

EU Commission granted orphan drug status for SENS-401

Release Date: 10 December 2016

Sensorian pharmaceuticals announced that European Commission has granted orphan drug designation in Europe for SENS-401 for the treatment of sudden sensorineural hearing loss. The European Commission grants orphan medicinal product statu...

Read More

---

FDA grants orphan drug status to Diazepam Buccal soluble film

Release Date: 09 December 2016

MonoSol Rx, a leading pharmaceutical company has announced that U.S Food and Drug Administration (FDA) have granted orphan drug designation to Diazepam Buccal soluble film to treat acute retentive seizures. The agency is planning to init...

Read More

---

FDA grants orphan drug status to ARMO’s AM0010

Release Date: 08 December 2016

ARMO Biosciences Inc., a clinical stage biotechnology company declared that it’s leading immune-oncology drug, AM0010 (PEGylated Interleukin-10), has been granted orphan drug designation by U.S Food and Drug Administration for the ...

Read More

---

AbbVie receives orphan status for ABBV-006 in U.S

Release Date: 07 December 2016

The U.S Food and Drug Administration have granted orphan drug designation to ABBV-006, developed by AbbVie pharmaceuticals for the treatment of Crohn’s Disease in pediatric patients. The drug is currently in its investigational pha...

Read More

---

FDA grants orphan drug status to PRX-OTC by PhaseRx

Release Date: 06 December 2016

PhaseRx, a biopharmaceutical company announced that its leading product, PRX-OTC has been granted orphan drug designation for the treatment of ornithine transcarbamylase deficiency by U.S Food and Drug Administration (FDA).

...

Read More

---

Ofev receives orphan drug status for Potential Scleroderma

Release Date: 05 December 2016

Ofev, a kinase inhibitor, has been declared as an orphan drug by European Commission and US Food and Drug Administration for the treatment of potential scleroderma and related interstitial lung diseases. The drug is currently in its phas...

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |